Method of diagnosing and treating Epstein Barr virus-based myalgic encephalomyelitis chronic fatigue syndrome patients
First Claim
1. A method of identifying a Epstein-Barr virus (EBV) subset of Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patients, the method comprising the step of:
- incubating EBV Early Antigen, Diffuse and at least one of EBV encoded DNA polymerase or EBV encoded dUTPase with a sample from a Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patient, where the EBV Early Antigen, Diffuse are covalently coupled to microspheres and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase are covalently coupled to microspheres that are different from the EBV Early Antigen, Diffuse coupled microspheres;
detecting binding of serum antibodies from the sample to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase; and
identifying the patient with Epstein Barr Abortive Lytic Replication when binding of the serum antibodies to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase is detected.
0 Assignments
0 Petitions
Accused Products
Abstract
A method of diagnosing a subset of Epstein Barr Virus, Myalgic Encephalomyelitis Chronic Fatigue Syndrome (ME/CFS) patients through a multi-prong clinical/serological analysis is provided wherein Epstein Barr Virus Abortive Lytic Replication (EBV) is determined as the specific causal agent through the use of serum antibodies to EBV encoded dUTPase and serum antibodies to EBV DNA Polymerase as molecular markers. A method of treating patients diagnosed with Epstein Barr Virus Abortive Lytic Replication (EBV), Myalgic Encephalomyelitis Chronic Fatigue Syndrome (ME/CFS) with specific antiviral nucleosides is also provided, to alleviate the condition.
-
Citations
15 Claims
-
1. A method of identifying a Epstein-Barr virus (EBV) subset of Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patients, the method comprising the step of:
-
incubating EBV Early Antigen, Diffuse and at least one of EBV encoded DNA polymerase or EBV encoded dUTPase with a sample from a Myalgic Encephalomyelitis-Chronic Fatigue Syndrome patient, where the EBV Early Antigen, Diffuse are covalently coupled to microspheres and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase are covalently coupled to microspheres that are different from the EBV Early Antigen, Diffuse coupled microspheres; detecting binding of serum antibodies from the sample to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase; and identifying the patient with Epstein Barr Abortive Lytic Replication when binding of the serum antibodies to the EBV Early Antigen, Diffuse and the at least one of EBV encoded DNA polymerase or EBV encoded dUTPase is detected. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
Specification